Abstract
The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myelogenous leukemia (CML) has profoundly improved prognosis. In recent years, a numer of studies have been conducted to demonstrate the possibility and safety of TKI cessation in well responding patients. Strict criteria for when to stop TKI therapy in clinical practice are not easily defined. Despite many doubts, it seems that achieving treatment-free remission may become a standard part of CML treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
